Redin, Esther
Sridhar, Harsha
Zhan, Yingqian A.
Pereira Mello, Barbara
Zhong, Hong
Durani, Vidushi
Sabet, Amin
Manoj, Parvathy
Linkov, Irina
Qiu, Juan
Koche, Richard P.
de Stanchina, Elisa
Astorkia, Maider
Betel, Doron
Quintanal-Villalonga, Álvaro
Rudin, Charles M.
Article History
Received: 28 April 2024
Accepted: 3 July 2024
First Online: 30 July 2024
Declarations
:
: All in vivo experiments were performed at Memorial Sloan Kettering Cancer Center (MSKCC) following Animal Care and Use Committee guidelines.
: Not applicable.
: AQV has received honoraria from Astra Zeneca. CMR has consulted regarding oncology drug development with AbbVie, Amgen, Astra Zeneca, D2G, Daiichi Sankyo, Epizyme, Genentech/Roche, Ipsen, Jazz, Kowa, Lilly, Merck, and Syros. He serves on the scientific advisory boards of Auron, Bridge Medicines, DISCO, Earli, and Harpoon Therapeutics. All other authors declare no conflicts of interest.